Research  >  Labs & groups  >  Neuropsychopharmacology  >  About the neuropsychopharmacology research group

About the neuropsychopharmacology research group

Neuropsychiatric symptoms are common sequelae of many medical and neurological illnesses such as stroke, coronary artery disease and dementia.

Neuropsychopharmacology group

The neuropsychopharmacology research group at Sunnybrook Research Institute (SRI), under the direction of Dr. Nathan Herrmann and Dr. Krista Lanctôt, aims to optimize the psychopharmacological management of neuropsychiatric symptoms by:

  1. determining the underlying neurobiology of neuropsychiatric symptoms;
  2. examining predictors of treatment response;
  3. using novel pharmacological agents; and
  4. considering adverse drug events carefully.

We use a variety of tools including neuroimaging, pharmacogenetics and pharmacologic challenges in combination with pharmacotherapeutic trials.

Our research will contribute to our understanding of the link between dysfunction in various neurotransmitters and neuropsychiatric symptoms. It may allow us to predict response to medications based on behavioral subtypes and at a broader level, it may provide the background for novel therapies.